TALPHERA INC (TLPH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.200.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · TLPH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 604.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
TLPH — officer change
Dated 2026-06-23
The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.
Why it matters: Updates on compliance are key for Talphera to stay listed. Not following rules could lead to delisting and loss of investor trust.
Worry ifTalphera says it has fixed Nasdaq compliance issues.
Less concerning ifTalphera does not fix compliance issues, risking delisting.
Why it matters: The results will show if Talphera can control expenses and improve financial performance. This is vital for investor sentiment.
Watch forQ2 results show a reduction in net loss compared to Q1 2026.
Also watch forQ2 results show an increase in net loss compared to Q1 2026.
Why it matters: Higher cash burn could signal financial strain. This may affect future operations and investor sentiment.
Worry ifTotal cash operating costs go over $18 million for 2026.
Less concerning ifTotal cash operating costs stay between $17 million and $18 million.
Why it matters: A drop in cash could signal financial stress and affect ongoing clinical trials.
Worry ifCash and investments remain above $15 million in the next quarter.
Less concerning ifCash and investments fall below $15 million.
Why it matters: If expenses exceed $18M, it shows management struggles to control costs. This could lead to deeper losses.
Worry ifQ2 operating costs were more than $18M.
Less concerning ifQ2 operating expenses were $17M or less.
Why it matters: Earnings results will show the company's financial health and performance.
Watch forQ2 earnings are much better than Q1 results.
Also watch forQ2 earnings show a decline compared to Q1 results.
Why it matters: Progress on this trial is key for product development. Delays could hurt future growth prospects.
Watch forThey shared good news about trial milestones and data releases.
Also watch forNo updates or delays in trial progress.
Why it matters: Fixing compliance problems is important for Talphera to keep its listing. This impacts investor trust and access to funds.
Worry ifManagement will announce plans to fix Nasdaq compliance problems.
Less concerning ifSilence or bad news about Nasdaq compliance status will be a concern.
Why it matters: Completing the study is key for nafamostat's market entry. It shows Talphera's progress.
Supportive ifEnrollment reaches 100% by the end of 2026.
Worry ifEnrollment completion is delayed beyond 2026.
Why it matters: New research shows more CRRT procedures. This could mean a bigger market for nafamostat.
Supportive ifMarket research shows over 200,000 CRRT procedures happen each year in the U.S.
Worry ifMarket research shows fewer than 200,000 annual U.S. CRRT procedures.
Why it matters: Controlling costs is key for Talphera's finances and future funding.
Worry ifCombined R&D and SG&A expenses remain within the $17M-$18M range.
Less concerning ifCombined R&D and SG&A expenses exceed $18M.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$241 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $859 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,053 loss on $10,000 · 50.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.